DD261844A1 - Verfahren zur praezipitation von fibrinmonomeren - Google Patents

Verfahren zur praezipitation von fibrinmonomeren Download PDF

Info

Publication number: DD261844A1
Authority: DD; German Democratic Republic
Prior art keywords: precipitation; centrifuged; fibrin monomers; netropsin; precipitant
Prior art date: 1986-07-09

Application number

DD86292298A

Other languages

German (de)

English (en)

Inventor

Klaus Eckardt

Marlena Stepanauskas

Heinz Thrum

Gottfried Toepfer

Andreas Seifert

Manfred Schulze

Udo Funke

Original Assignee

Adw Ddr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-09

Filing date

1986-07-09

Publication date

1988-11-09

1986-07-09 Application filed by Adw Ddr filed Critical Adw Ddr

1986-07-09 Priority to DD86292298A priority Critical patent/DD261844A1/de

1987-06-30 Priority to JP62163834A priority patent/JPS6327762A/ja

1987-07-06 Priority to EP87109687A priority patent/EP0253255A3/fr

1987-07-09 Priority to US07/071,799 priority patent/US4960694A/en

1988-11-09 Publication of DD261844A1 publication Critical patent/DD261844A1/de

Links

238000000034 method Methods 0.000 title claims abstract description 17
IDBIFFKSXLYUOT-UHFFFAOYSA-N netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 claims abstract description 16
238000001556 precipitation Methods 0.000 claims abstract description 13
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 12
108010073385 Fibrin Proteins 0.000 claims abstract description 11
102000009123 Fibrin Human genes 0.000 claims abstract description 11
229950003499 fibrin Drugs 0.000 claims abstract description 11
239000000178 monomer Substances 0.000 claims abstract description 10
108010042309 Netropsin Proteins 0.000 claims abstract description 9
210000004369 blood Anatomy 0.000 claims abstract description 5
239000008280 blood Substances 0.000 claims abstract description 5
230000003115 biocidal effect Effects 0.000 claims abstract description 4
FSUPKDUNLKQBCN-UHFFFAOYSA-N 1H-pyrrole-2-carboximidamide Chemical class NC(=N)C1=CC=CN1 FSUPKDUNLKQBCN-UHFFFAOYSA-N 0.000 claims abstract description 3
239000003146 anticoagulant agent Substances 0.000 claims abstract description 3
229940127219 anticoagulant drug Drugs 0.000 claims abstract description 3
239000003795 chemical substances by application Substances 0.000 claims abstract 2
238000006243 chemical reaction Methods 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims description 2
UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 claims description 2
230000001376 precipitating effect Effects 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
108010042747 stallimycin Proteins 0.000 claims description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
239000007853 buffer solution Substances 0.000 claims 1
238000001514 detection method Methods 0.000 abstract description 6
239000002244 precipitate Substances 0.000 abstract description 5
239000003242 anti bacterial agent Substances 0.000 abstract description 3
201000010099 disease Diseases 0.000 abstract description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
238000002156 mixing Methods 0.000 abstract description 2
238000003745 diagnosis Methods 0.000 abstract 1
108010081391 Ristocetin Proteins 0.000 description 4
BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
229950004257 ristocetin Drugs 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
QZOOZUGORDEYCC-UHFFFAOYSA-N 4-[[4-[[1-amino-2-(diaminomethylideneamino)ethylidene]amino]-1-methylpyrrole-2-carbonyl]amino]-n-(3-amino-3-oxopropyl)-1-methylpyrrole-2-carboxamide;hydron;chloride Chemical compound Cl.C1=C(C(=O)NCCC(N)=O)N(C)C=C1NC(=O)C1=CC(N=C(N)CN=C(N)N)=CN1C QZOOZUGORDEYCC-UHFFFAOYSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
VMDFASMUILANOL-WXXKFALUSA-N bisoprolol fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VMDFASMUILANOL-WXXKFALUSA-N 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
108010073651 fibrinmonomer Proteins 0.000 description 1
238000001879 gelation Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

DD86292298A 1986-07-09 1986-07-09 Verfahren zur praezipitation von fibrinmonomeren DD261844A1 (de)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
DD86292298A DD261844A1 (de)	1986-07-09	1986-07-09	Verfahren zur praezipitation von fibrinmonomeren
JP62163834A JPS6327762A (ja)	1986-07-09	1987-06-30	血中フィブリン単量体検出用テスト配合剤および検出方法
EP87109687A EP0253255A3 (fr)	1986-07-09	1987-07-06	Procédé et trousse d'essai de détection de monomères de fibrine dans le sang
US07/071,799 US4960694A (en)	1986-07-09	1987-07-09	Test combination and method of detecting fibrin monomers in blood

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DD86292298A DD261844A1 (de)	1986-07-09	1986-07-09	Verfahren zur praezipitation von fibrinmonomeren

Publications (1)

Publication Number	Publication Date
DD261844A1 true DD261844A1 (de)	1988-11-09

Family

ID=5580752

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD86292298A DD261844A1 (de)	1986-07-09	1986-07-09	Verfahren zur praezipitation von fibrinmonomeren

Country Status (4)

Country	Link
US (1)	US4960694A (fr)
EP (1)	EP0253255A3 (fr)
JP (1)	JPS6327762A (fr)
DD (1)	DD261844A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1091315A (zh) *	1992-10-08	1994-08-31	E·R·斯奎布父子公司	血纤维蛋白封闭剂组合物及其使用方法
US5441892A (en) *	1992-10-15	1995-08-15	Medtronic Hemptec, Inc.	Blood clot mass measuring technique
JP3808500B2 (ja) *	1994-02-22	2006-08-09	キューレータズオブディユニバーシティオブミズーリ	分離剤としての大環状抗生物質
US6436655B1 (en)	1998-02-09	2002-08-20	Medical Devices Corporation	Rapid quantitative measurement of soluble fibrin in opaque body fluids
WO2005116623A2 (fr) *	2004-05-17	2005-12-08	Medtronic, Inc.	Systeme de determination de l'heparine selon les points d'intervention

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3990947A (en) *	1975-03-07	1976-11-09	Warner-Lambert Company	Composition for detecting fibrinogen, fibrinogen split products and fibrin split products
US4145185A (en) *	1977-02-25	1979-03-20	Research Triangle Institute	Reagents for screening tests and bioassay of von Willebrand's factor (platelet aggregating factor) in blood plasmas
US4210420A (en) *	1978-11-13	1980-07-01	Ortho Diagnostics Inc.	Detection of fibrin monomer and composition therefor
DE3017707A1 (de) *	1980-05-08	1981-11-12	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren und reagens zum nachweis von fibrinmonomer
DE3330699A1 (de) *	1983-08-25	1985-03-07	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren zur gleichzeitigen bestimmung von fibrinogen und fibrinogen-spaltprodukten im plasma
DE3430906A1 (de) *	1984-08-22	1986-02-27	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren zur bestimmung von fibrinmonomer in plasma
GB8517922D0 (en) *	1985-07-16	1985-08-21	Erba Farmitalia	Carboxamido derivatives

1986
- 1986-07-09 DD DD86292298A patent/DD261844A1/de not_active IP Right Cessation
1987
- 1987-06-30 JP JP62163834A patent/JPS6327762A/ja active Pending
- 1987-07-06 EP EP87109687A patent/EP0253255A3/fr not_active Withdrawn
- 1987-07-09 US US07/071,799 patent/US4960694A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US4960694A (en)	1990-10-02
EP0253255A2 (fr)	1988-01-20
JPS6327762A (ja)	1988-02-05
EP0253255A3 (fr)	1990-06-13

Legal Events

Date	Code	Title
1992-08-27	EPAE	Change in the person, name or address of the patentee
1992-08-27	UW	Conversion of economic patent into exclusive patent
2000-02-17	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
Hemker et al.	1968	Kinetic aspects of the interaction of blood clotting enzymes: III. Demonstration of an inhibitor of prothrombin conversion in vitamin K deficiency
DE69520569T2 (de)	2001-10-04	Mittel für die behandlung von störungen des blutgerinnungsprozess
DE69227055T2 (de)	1999-04-22	Verfahren zur Herstellung in industriellem Massstab eines Konzentrates von hochgereinigtem, standardisiertem humanen von Willebrand Faktor, das für therapeutische Anwendung geeignet ist
DE69033033T2 (de)	1999-10-28	Verbesserte kontrollverfahren für stabile blutkoagulation
EP0203509B1 (fr)	1991-04-03	Procédé pour la détermination quantitative de la protéine-C et une préparation activatrice pour sa réalisation
DE2243688B2 (de)	1978-06-15	Verfahren zur Isolierung von Antithrombin
EP0018353B1 (fr)	1984-01-25	Procédé de préparation de fractions de plasma exemptes d'effets secondaires
DE2461969A1 (de)	1976-07-08	Stabiles blutplasma, verfahren zu dessen herstellung und seine verwendung als vergleichsplasma bei gerinnungs- untersuchungen
EP0023607A2 (fr)	1981-02-11	Procédé de préparation d'une solution de collagène, une telle solution et son utilisation
EP0780687A2 (fr)	1997-06-25	Procédé de préparation d'un étalon synthétique pour des immuno-essais sandwich
Mohri	1987	Acquired von Willebrand disease in patients with polycythemia rubra vera
DE2641840C2 (de)	1986-07-24	Verfahren zum Reinigen eines Antiserums
DE3788944T2 (de)	1994-05-26	Verfahren zur herstellung eines koagulationsaktiven komplexes vom faktor viii-fragment.
Johnson et al.	1958	A new approach to the thrombocytopathies. Thrombocytopathy A
DD261844A1 (de)	1988-11-09	Verfahren zur praezipitation von fibrinmonomeren
EP0625908A1 (fr)	1994-11-30	Antidote pour l'hirudine et les inhibiteurs synthetiques de la thrombine
EP0626070B1 (fr)	1996-04-03	Procede de determination de l'hirudine et des inhibiteurs synthetiques de la thrombine
DE2654189B2 (de)	1979-03-08	Verfahren zur in-vitro-Bestimmung der biologischen Aktivität von Faktor Xa-Inhibitor im Blut
EP0280135B1 (fr)	1991-09-25	Protéine C-inhibiteur (PCI) comme agent pharmaceutique et diagnostic, procédé de préparation d'un tel agent pharmaceutique ou diagnostic ainsi qu'un milieu contenant le PCI
EP1752772A1 (fr)	2007-02-14	Procédé pour détermination d'héparine basé sur facteur Xa utilisant un composant pour la modification d'héparine
DE69431430T2 (de)	2003-05-22	Faktor XIII zur Behandlung von Hautwunden
DE69033944T2 (de)	2002-09-19	Mittel zur direkten chemischen Bindung des D-Dimers aus einer biologischen Probe zwecks Diagnostik und Überwachung von thrombolytischen und hyperkoagulablen Zuständen
DE3024270C2 (de)	1984-10-11	Zusammensetzung zur Bestimmung des menschlichen Erythropoietins und Verfahren zu dessen Bestimmung
Hemker et al.	1968	Kinetic aspects of the interaction of blood clotting enzymes
DE19634312A1 (de)	1998-02-26	Verfahren zur Herstellung von Faktor V-Mangelplasma und ein so erhaltenes Mangelplasma